Literature DB >> 25152271

The role of the microbiome in exacerbations of chronic lung diseases.

Robert P Dickson1, Fernando J Martinez2, Gary B Huffnagle3.   

Abstract

Culture-independent microbiological techniques have shown a previously unappreciated complexity to the bacterial microbiome of the respiratory tract that forces reconsideration of the interactions between host, bacteria, and the pathogenesis of exacerbations of chronic lung disease. The composition of the lung microbiome is determined by microbial immigration, elimination, and relative growth rates of its members. All these factors change dramatically in chronic lung disease and further during exacerbations. Exacerbations lack the features of bacterial infections, including increased bacterial burden and decreased diversity of microbial communities. We propose that exacerbations are occasions of respiratory tract dysbiosis--a disorder of the respiratory tract microbial ecosystem with negative effects on host biology. Respiratory tract dysbiosis provokes a dysregulated host immune response, which in turn alters growth conditions for microbes in airways, promoting further dysbiosis and perpetuating a cycle of inflammation and disordered microbiota. Differences in the composition of baseline respiratory tract microbiota might help to explain the so-called frequent-exacerbator phenotype observed in several disease states, and might provide novel targets for therapeutic intervention.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25152271      PMCID: PMC4166502          DOI: 10.1016/S0140-6736(14)61136-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  128 in total

1.  Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate virulence and persistence of Pseudomonas aeruginosa.

Authors:  Kate B Twomey; Oisin J O'Connell; Yvonne McCarthy; J Maxwell Dow; George A O'Toole; Barry J Plant; Robert P Ryan
Journal:  ISME J       Date:  2011-12-01       Impact factor: 10.302

2.  Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota.

Authors:  Amanda F Goddard; Benjamin J Staudinger; Scot E Dowd; Amruta Joshi-Datar; Randall D Wolcott; Moira L Aitken; Corinne L Fligner; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-07       Impact factor: 11.205

3.  Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients.

Authors:  Michael J Cox; Martin Allgaier; Byron Taylor; Marshall S Baek; Yvonne J Huang; Rebecca A Daly; Ulas Karaoz; Gary L Andersen; Ronald Brown; Kei E Fujimura; Brian Wu; Diem Tran; Jonathan Koff; Mary Ellen Kleinhenz; Dennis Nielson; Eoin L Brodie; Susan V Lynch
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

4.  Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush.

Authors:  E Monsó; J Ruiz; A Rosell; J Manterola; J Fiz; J Morera; V Ausina
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

Review 5.  Microbial community profiling for human microbiome projects: Tools, techniques, and challenges.

Authors:  Micah Hamady; Rob Knight
Journal:  Genome Res       Date:  2009-04-21       Impact factor: 9.043

6.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

Review 7.  Microbiota abnormalities in inflammatory airway diseases - Potential for therapy.

Authors:  Eva S Gollwitzer; Benjamin J Marsland
Journal:  Pharmacol Ther       Date:  2013-08-19       Impact factor: 12.310

8.  Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans.

Authors:  Jacobien J Hoogerwerf; Alex F de Vos; Paul Bresser; Jaring S van der Zee; Jennie M Pater; Anita de Boer; Michael Tanck; Daniel L Lundell; Chung Her-Jenh; Christian Draing; Sonja von Aulock; Tom van der Poll
Journal:  Am J Respir Crit Care Med       Date:  2008-04-10       Impact factor: 21.405

9.  Chapter 12: Human microbiome analysis.

Authors:  Xochitl C Morgan; Curtis Huttenhower
Journal:  PLoS Comput Biol       Date:  2012-12-27       Impact factor: 4.475

10.  Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections.

Authors:  Christopher D Sibley; Kangmin Duan; Carrie Fischer; Michael D Parkins; Douglas G Storey; Harvey R Rabin; Michael G Surette
Journal:  PLoS Pathog       Date:  2008-10-24       Impact factor: 6.823

View more
  160 in total

Review 1.  Homeostasis and its disruption in the lung microbiome.

Authors:  Robert P Dickson; John R Erb-Downward; Gary B Huffnagle
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-02       Impact factor: 5.464

Review 2.  The Microbiome and the Respiratory Tract.

Authors:  Robert P Dickson; John R Erb-Downward; Fernando J Martinez; Gary B Huffnagle
Journal:  Annu Rev Physiol       Date:  2015-11-02       Impact factor: 19.318

Review 3.  The microbiome and critical illness.

Authors:  Robert P Dickson
Journal:  Lancet Respir Med       Date:  2015-12-12       Impact factor: 30.700

Review 4.  Understanding the role of the microbiome in chronic obstructive pulmonary disease: principles, challenges, and future directions.

Authors:  Yvonne J Huang; John R Erb-Downward; Robert P Dickson; Jeffrey L Curtis; Gary B Huffnagle; MeiLan K Han
Journal:  Transl Res       Date:  2016-06-23       Impact factor: 7.012

5.  Multi-omic meta-analysis identifies functional signatures of airway microbiome in chronic obstructive pulmonary disease.

Authors:  Zhang Wang; Yuqiong Yang; Zhengzheng Yan; Haiyue Liu; Boxuan Chen; Zhenyu Liang; Fengyan Wang; Bruce E Miller; Ruth Tal-Singer; Xinzhu Yi; Jintian Li; Martin R Stampfli; Hongwei Zhou; Christopher E Brightling; James R Brown; Martin Wu; Rongchang Chen; Wensheng Shu
Journal:  ISME J       Date:  2020-07-27       Impact factor: 10.302

6.  A Genomic Approach To Identify Klebsiella pneumoniae and Acinetobacter baumannii Strains with Enhanced Competitive Fitness in the Lungs during Multistrain Pneumonia.

Authors:  Mallory J Agard; Egon A Ozer; Andrew R Morris; Raul Piseaux; Alan R Hauser
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

Review 7.  Novel approaches are needed to develop tomorrow's antibacterial therapies.

Authors:  Brad Spellberg; John Bartlett; Rich Wunderink; David N Gilbert
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

8.  Intraalveolar Catecholamines and the Human Lung Microbiome.

Authors:  Robert P Dickson; John R Erb-Downward; Hallie C Prescott; Fernando J Martinez; Jeffrey L Curtis; Vibha N Lama; Gary B Huffnagle
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

9.  Spatial Variation in the Healthy Human Lung Microbiome and the Adapted Island Model of Lung Biogeography.

Authors:  Robert P Dickson; John R Erb-Downward; Christine M Freeman; Lisa McCloskey; James M Beck; Gary B Huffnagle; Jeffrey L Curtis
Journal:  Ann Am Thorac Soc       Date:  2015-06

Review 10.  Learning from other diseases: protection and pathology in chronic fungal infections.

Authors:  Teresa Zelante; Giuseppe Pieraccini; Lucia Scaringi; Franco Aversa; Luigina Romani
Journal:  Semin Immunopathol       Date:  2015-09-17       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.